John Nazarian
Psychiatry · West Hartford, CTNPI 1952311805
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,963 of the $78,961 with a category attached, or 83.5%. 13 manufacturers reported payments, led by Alkermes, Inc. at 39.6% of the total. Reporting peaked in 2019 at $23,022 and has fallen 97.7% since, to $524 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $337.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$31K
- Otsuka America Pharmaceutical, Inc.$21K
- AbbVie$14K
- Indivior Inc.$10K
- Johnson & Johnson$868
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$396
- plus $646 from 7 others
What the payments were for
- Speaking & faculty fees$65,96384%
- Travel & lodging$6,0898%
- Food & beverage$6,8319%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 40 | $31,244 |
| Otsuka America Pharmaceutical, Inc. | 49 | $21,144 |
| AbbVie(2 entities) | 65 | $14,360 |
| Indivior Inc. | 19 | $10,303 |
| Johnson & Johnson | 30 | $868 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $396 |
| Neurocrine Biosciences, Inc. | 6 | $256 |
| Teva Pharmaceuticals USA, Inc. | 9 | $244 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 1 | $34 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Orexo US, Inc. | 1 | $20 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$72,572
- ARISTADA$61,618
- ABILIFY MAINTENA$19,979
- VRAYLAR$13,399
- SUBLOCADE$10,281
- ARISTADA INITIO$3,672
- REXULTI$1,205
- SPRAVATO$238
- CAPLYTA$229
- INGREZZA$127
How this compares
$78,961 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 14 | $18,339 |
| Chlorpromazine Hcl | 11 | $2,011 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $2,000 |
| Clozapine | 31 | $1,316 |
| Buprenorphine Hcl | 15 | $1,117 |
| Aripiprazole | 20 | $681 |
| Bupropion XlBupropion Hcl | 26 | $421 |
| Lamotrigine | 37 | $342 |
| Escitalopram Oxalate | 24 | $304 |
| Buspirone Hcl | 13 | $275 |
| Hydroxyzine Hcl | 14 | $180 |
| Zolpidem Tartrate | 19 | $158 |
| Clonazepam | 17 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $14,360 | $18,33914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in West Hartford
- Irene AbramovichWest Hartford$352K
- Dale WallingtonWest Hartford$31K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.